Given that genomic amplification of OSR2 occurs in as many as 30% of prostate cancer patients (Supplemental Fig. S7I; Grasso et al. 2012; The Cancer Genome Atlas Research Network 2015; Kumar et al. 2016; Armenia et al. 2018; Ren et al. 2018; Abida et al. 2019), we next examined the impact of OSR2 overexpression on the proliferation of prostate cancer cells. Here, OSR2 is linked to prostate cancer.